Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01110863 · ClinicalTrials.gov registry record
Characterization of Proliferating Compartment in B-Cell Patients and in Healthy Aging Subjects
A clinical trial, sponsored by Northwell Health.
- Completed
- Registry status
- 90
- Enrollment target
NCT01110863 is a clinical trial that has completed, run by Northwell Health. The registered enrollment target is 90 participants.
The verdict
NCT01110863 has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- 90 participants
- Enrollment target
Study Summary
By ingesting a non-radioactive and non-toxic compound "heavy water" for 6 weeks, the DNA of newly developed cells in the body of subjects with B-cell chronic lymphocytic leukemia can be labeled and followed by performing routine blood draws at specified time intervals. By using mass spectrometric analysis we can measure how quickly new B-CLL cells are generated in the bone marrow and how quickly they leave the blood, a measure of cell turnover. This will help us to better understand the unique characteristics of this disease process.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2005-12 |
| Est. Completion | 2016-02-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01110863
The ClinicalTrials.gov registry entry for NCT01110863 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01110863 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01110863 about?
NCT01110863 is a clinical study titled "Characterization of Proliferating Compartment in B-Cell Patients and in Healthy Aging Subjects". By ingesting a non-radioactive and non-toxic compound "heavy water" for 6 weeks, the DNA of newly developed cells in the body of subjects with B-cell chronic lymphocytic leukemia can be labeled and followed by performing routine blood draws at specified time intervals. By using mass spectrometric an...
What is the current status of trial NCT01110863?
This trial is currently completed. The enrollment target is 90 participants. The study started on 2005-12. Estimated completion is 2016-02-12.
Who is sponsoring clinical trial NCT01110863?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.